Clostridium butyricum MIYAIRI
Selected indexed studies
- The biotherapeutic Clostridium butyricum MIYAIRI 588 strain potentiates enterotropism of Rorγt(+)Treg and PD-1 blockade efficacy. (Gut Microbes, 2024) [PMID:38385162]
- Clostridium butyricum MIYAIRI 588 alleviates periodontal bone loss in mice with diabetes mellitus. (Ann N Y Acad Sci, 2023) [PMID:37658670]
- Clostridium butyricum MIYAIRI 588 Reduces Colorectal Adenomatous Polyp Recurrence: A Randomized Crossover Trial. (Oncol Res, 2025) [PMID:41425719]
_Worker-drafted node — pending editorial review._
Connections
Clostridium butyricum MIYAIRI helps
Sources
- Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer. (2020) pubmed
- The biotherapeutic Clostridium butyricum MIYAIRI 588 strain potentiates enterotropism of Rorγt(+)Treg and PD-1 blockade efficacy. (2024) pubmed
- Clostridium butyricum MIYAIRI 588 alleviates periodontal bone loss in mice with diabetes mellitus. (2023) pubmed
- Clostridium butyricum MIYAIRI 588 Reduces Colorectal Adenomatous Polyp Recurrence: A Randomized Crossover Trial. (2025) pubmed
- Clostridium Butyricum miyairi bacteriocin treatment for Clostridioides difficile infections with clinical isolates: Insights from in vitro, ex vivo, and mouse model studies. (2025) pubmed
- Supplemental Clostridium butyricum MIYAIRI 588 Affects Intestinal Bacterial Composition of Finishing Pigs. (2022) pubmed
- Combination therapy with levofloxacin and the probiotic Clostridium butyricum MIYAIRI 588 enhances immune checkpoint inhibitor efficacy. (2025) pubmed
- Clostridium butyricum miyairi 588 has preventive effects on chronic social defeat stress-induced depressive-like behaviour and modulates microglial activation in mice. (2019) pubmed
- Clostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation. (2024) pubmed
- Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study. (2025) pubmed